Cargando…

Secondary Dyslipidemia In Obese Children - Is There Evidence For Pharmacological Treatment?

Detalles Bibliográficos
Autor principal:	Tanaka, Ana Cristina Sayuri
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Sociedade Brasileira de Cardiologia - SBC 2018
Materias:	Short Editorial
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6173334/ https://www.ncbi.nlm.nih.gov/pubmed/30379254 http://dx.doi.org/10.5935/abc.20180187

Ejemplares similares

Secondary Dyslipidemia In Obese Children - Is There Evidence For Pharmacological Treatment?
por: Radaelli, Graciane, et al.
Publicado: (2018)

Challenges in the Pharmacologic Management of Obesity and Secondary Dyslipidemia in Children and Adolescents
por: Kennedy, Mary Jayne, et al.
Publicado: (2013)

Frequency of secondary dyslipidemia in obese children
por: Korsten-Reck, Ulrike, et al.
Publicado: (2008)

High Prevalence of Dyslipidemia in Children and Adolescents: Opportunity for Prevention
por: Mangili, Leonardo
Publicado: (2020)

Editorial: Secondary Dyslipidemias
por: Elisaf, Moses, et al.
Publicado: (2011)

Dyslipidemia: evidence of efficacy of the pharmacological and non-pharmacological treatment in the elderly
por: Gravina, Claudia F, et al.
Publicado: (2012)

Pharmacologic Treatment of Obesity
por: Halpern, Alfredo, et al.
Publicado: (2011)

Can Non-Pharmacological Treatment Promote Additional Benefit for Children with Familial Hypercholesterolemia Treated with Statins?
por: Antoniazzi, Luiza
Publicado: (2018)

Overview of Pharmacologic Therapy for the Treatment of Dyslipidemia
por: Lipsy, Robert J.
Publicado: (2003)

New guidelines and evidence for prevention and treatment of dyslipidemia and atherosclerotic cardiovascular disease in China()
por: Hu, Da-Yi
Publicado: (2016)

Dyslipidemia in Iranian overweight and obese children
por: Ghergerehchi, Robabeh
Publicado: (2009)

Dyslipidemia, Obesity, and Ethnicity in Mexican Children
por: Costa-Urrutia, Paula, et al.
Publicado: (2021)

Aspects of Non-Pharmacological Treatment in Peripheral Arterial Disease
por: Alves, Maria Janieire de N. Nunes, et al.
Publicado: (2019)

Management of Dyslipidemia in Secondary Prevention of Cardiovascular Disease: The Gap between Theory and Practice
por: Santangelo, Gloria, et al.
Publicado: (2022)

Insulin Resistance, Dyslipidemia and Cardiovascular Changes in a Group of Obese Children
por: Pires, António, et al.
Publicado: (2015)

Amlamax™ in the Management of Dyslipidemia in Humans
por: Antony, B., et al.
Publicado: (2008)

Dyslipidemia and Breast Cancer
por: Aggarwal, Neelam, et al.
Publicado: (2018)

Endothelial stiffening in dyslipidemia
por: Le Master, Elizabeth, et al.
Publicado: (2019)

Dyslipidemia and Fatty Liver Disease in Overweight and Obese Children
por: Deeb, Asma, et al.
Publicado: (2018)

Prevalence of Dyslipidemia and Associated Factors in Obese Children and Adolescents
por: Elmaoğulları, Selin, et al.
Publicado: (2015)

Dyslipidemia is Associated with Unfit and Overweight-Obese Children and Adolescents
por: Reuter, Cézane Priscila, et al.
Publicado: (2016)

Atherogenic Dyslipidemia and Cardiovascular Risk Factors in Obese Children
por: D'Adamo, Ebe, et al.
Publicado: (2015)

An Update on the Role of Arterial Stiffness in Heart Failure and the Treatment of Dyslipidemia
por: Feola, Mauro
Publicado: (2023)

The Draupadi of dyslipidemia: Familial hypercholesterolemia
por: Kalra, Sanjay, et al.
Publicado: (2016)

Clinical and diagnostic importance of dyslipidemia in children and adolescents during the coronavirus disease 2019 pandemic
por: Kim, Eun Young
Publicado: (2022)

Early echocardiographic screening for subclinical myocardial dysfunction in children and adolescents with dyslipidemia: why and when?
por: Lee, Hyun Gyung, et al.
Publicado: (2022)

Association of pharmacological treatments for hypertension, diabetes, and dyslipidemia with health checkup participation and identification of disease control factors among older adults in Tokyo, Japan
por: Mitsutake, Seigo, et al.
Publicado: (2019)

Dyslipidemia links obesity to early cerebral neurochemical alterations
por: Haley, Andreana P., et al.
Publicado: (2013)

The Endocannabinoid System, an Underexploited and Promising Niche for the Pharmacological Treatment of Obesity and Metabolic Diseases
por: Gómez-Ambrosi, Javier
Publicado: (2022)

Physical Exercise as a Non-Pharmacological Intervention for Attenuating Obesity-Related Complications in Children and Adolescents
por: Calcaterra, Valeria, et al.
Publicado: (2022)

Obesity and Dyslipidemia in South Asians
por: Misra, Anoop, et al.
Publicado: (2013)

Dyslipidemia and Obesity in Ischemic Stroke
por: Gajurel, Bikram P, et al.
Publicado: (2023)

Role of Complementary and Alternative Medicine in Controlling Dyslipidemia
por: Qidwai, Waris, et al.
Publicado: (2014)

Time to consider an Asian guideline for management of dyslipidemia?
por: Yokote, Koutaro, et al.
Publicado: (2012)

Diets, Foods and Food Components’ Effect on Dyslipidemia
por: Fogacci, Federica, et al.
Publicado: (2021)

Sex Hormone-Binding Globulin Is Associated with Obesity and Dyslipidemia in Prepubertal Children
por: Park, Gihong, et al.
Publicado: (2020)

Drugs Involved in Dyslipidemia and Obesity Treatment: Focus on Adipose Tissue
por: Dias, Sofia, et al.
Publicado: (2018)

In Silico Pharmacology for Evidence-Based and Precision Medicine
por: Spanakis, Marios
Publicado: (2023)

Management of dyslipidemia in children
por: Kalra, Sanjay, et al.
Publicado: (2009)

Dyslipidemia in Obesity: Mechanisms and Potential Targets
por: Klop, Boudewijn, et al.
Publicado: (2013)

Cannot write session to /tmp/vufind_sessions/sess_s7s40albat2jq204sd045r13qg